Trial Profile
A multi-center controlled study comparing the efficacy of sunitinib and imatinib following cytoreductive resection in gastrointestinal stromal tumor patients with progression on imatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 29 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology